Lilly Reports Positive Omvoh Disease Control Data, Schedules Q3 Results For October 29; Stock Up

Eli Lilly's Omvoh (mirikizumab) showed positive results in phase 3 trials for ulcerative colitis and Crohn's disease, achieving treatment goals and corticosteroid-free deep remission at one year, according to the company.

Adlai Nortye Group (ANL) partners with Eli Lilly (LLY) and Merck KGaA (MKKGY) to evaluate AN4035 in combination with cetuximab for solid tumors. The Phase I trial will assess safety and efficacy, with Lilly and Merck supplying the drug. ANL's stock closed at $10.88, up 3.40% in pre-market trading.

Eli Lilly (LLY) reported one-year data for Omvoh in ulcerative colitis and Crohn's disease. In LUCENT-2, 27.7% of patients achieved comprehensive disease control vs. 14% on placebo. For biologic-failure patients, 23.4% achieved control vs. 9.4% on placebo. In VIVID-1, 20% of Crohn's patients achieved corticosteroid-free deep remission. LLY stock was up 1.26% pre-market.

Eli Lilly's Omvoh (mirikizumab-mrkz) showed positive results in treating ulcerative colitis and Crohn's disease. In trials, 27.7% of UC patients and 20.4% of Crohn's patients achieved specific remission goals. The drug is approved in 47 countries for these indications.

The UK's MHRA approved Eli Lilly's once-weekly insulin efsitora alfa (Onswik) for type 2 diabetes, reducing injections from 365 to 52 yearly. NICE recommends it for NHS use, citing comparable glucose control to daily insulins and potential cost savings. It may benefit hundreds of thousands of patients, especially those needing assistance with daily injections.

Eli Lilly's Omvoh (mirikizumab-mrkz) showed positive results in treating ulcerative colitis and Crohn's disease. In the LUCENT-2 study, 27.7% of UC patients achieved comprehensive disease control, while in VIVID-1, 20.4% of Crohn's patients achieved corticosteroid-free deep remission. Benefits were also seen in patients with prior biologic failure. The data will be presented at UEG Week 2026.